1. Home
  2. CNSP vs BGLC Comparison

CNSP vs BGLC Comparison

Compare CNSP & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CNS Pharmaceuticals Inc.

CNSP

CNS Pharmaceuticals Inc.

HOLD

Current Price

$7.90

Market Cap

4.3M

Sector

Health Care

ML Signal

HOLD

Logo BioNexus Gene Lab Corp

BGLC

BioNexus Gene Lab Corp

HOLD

Current Price

$4.17

Market Cap

10.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNSP
BGLC
Founded
2017
2017
Country
United States
Malaysia
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.3M
10.1M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
CNSP
BGLC
Price
$7.90
$4.17
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$20.00
N/A
AVG Volume (30 Days)
10.1K
201.4K
Earning Date
11-17-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$9,465,006.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
2.21
52 Week Low
$4.93
$2.01
52 Week High
$114.00
$15.60

Technical Indicators

Market Signals
Indicator
CNSP
BGLC
Relative Strength Index (RSI) 59.39 37.92
Support Level $6.11 $4.02
Resistance Level $8.10 $4.34
Average True Range (ATR) 0.48 0.26
MACD 0.18 0.00
Stochastic Oscillator 84.42 15.45

Price Performance

Historical Comparison
CNSP
BGLC

About CNSP CNS Pharmaceuticals Inc.

CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.

About BGLC BioNexus Gene Lab Corp

BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.

Share on Social Networks: